Population-based impact on overall survival after the introduction of docetaxel as standard therapy for metastatic castration resistant prostate cancer.

Zielinski, Robert R; Azad, Arun A; Chi, Kim N; Tyldesely, Scott

Zielinski, Robert R; Azad, Arun A; Chi, Kim N; Tyldesely, Scott.

Afiliação

Zielinski RR; BC Cancer Agency, Vancouver Centre, Department of Medical Oncology, British Columbia Cancer Agency, Vancouver BC;
Azad AA; BC Cancer Agency, Vancouver Centre, Department of Medical Oncology, British Columbia Cancer Agency, Vancouver BC;
Chi KN; BC Cancer Agency, Vancouver Centre, Department of Medical Oncology, British Columbia Cancer Agency, Vancouver BC; ; BC Cancer Agency, Vancouver Centre, Department of Radiation Oncology, University of British Columbia, Vancouver, BC.
Tyldesely S; BC Cancer Agency, Vancouver Centre, Department of Medical Oncology, British Columbia Cancer Agency, Vancouver BC; ; BC Cancer Agency, Vancouver Centre, Department of Radiation Oncology, University of British Columbia, Vancouver, BC.

Can Urol Assoc J ; 8(7-8): E520-3, 2014 Jul.

Article em En | MEDLINE | ID: mdl-25210555

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2014 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2014 Tipo de documento: Article